FDA Drafts Guidance On Safety-Data Musts For GRASE Sunscreen Actives
This article was originally published in The Rose Sheet
Time and extent applicants seeking GRASE status for UV filters should provide FDA with the kind of clinical safety data used to support approval of chronic-use cutaneous drug products, and nonclinical testing should focus on potential long-term adverse effects, according to newly released draft guidance required from the agency under the Sunscreen Innovation Act. FDA is particularly interested in receiving comments about final formulation safety testing it anticipates requiring under specified monograph conditions.
You may also be interested in...
Consumer access to SPF-infused wipes is shrinking following FDA warning letters last year to companies that have since discontinued cited products, which the agency says are unapproved drugs ineligible for OTC sunscreen drug review. It remains to be seen how the maker of KLENSKIN Shower-On sunscreen products will respond, with its entire business model hanging in the balance.
FDA officials and the Public Access to Sunscreen Coalition will meet Nov. 1 in effort to find common ground between FDA and outside scientists on standards for testing requirements of new sunscreens under one of four draft guidances the agency is scheduled to finalize by the end of the year.
Recent “alarmist reports” and studies regarding the state of the US sunscreen market and the merits of UV-protective products available to consumers are sending a potentially confusing message, which could discourage sunscreen use at a time of epidemic skin-cancer rates, the Personal Care Products Council suggests. The group hosted a webinar July 11 to clarify sunscreen regulations and promote daily use.